Johnson & Johnson(JNJ)

New York Stock Exchange
Sector: Healthcare | Industry: Drug Manufacturers - General
Johnson & Johnson logo

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Latest News & Analysis

Johnson & Johnson stock analysis: Nipocalimab, Darzalex impact, economic challenges, and dividend sustainability. #JNJ #StockAnalysis #Healthcare
Apr 9, 2025

Johnson & Johnson: Nipocalimab, DARZALEX®, and Economic Outlook

JNJ navigates innovation, economic challenges, and strategic dividend decisions. Nipocalimab's potential in gMG and DARZALEX®'s impact on multiple myeloma are key.

Read more →
Johnson & Johnson stock analysis: clinical trial success, strategic acquisitions, and legal challenges impacting JNJ investment profile.
Apr 4, 2025

Johnson & Johnson (JNJ): TREMFYA®, Acquisitions, and Market Analysis

Analysis of Johnson & Johnson (JNJ): TREMFYA® efficacy, Intra-Cellular Therapies acquisition, market resilience, and talc litigation impacts on JNJ stock.

Read more →
Johnson & Johnson stock analysis: legal challenges, strategic acquisitions, and investor outlook. JNJ stock news.
Apr 2, 2025

Johnson & Johnson (JNJ): Litigation, Acquisitions, and Investor Outlook

Johnson & Johnson (JNJ) navigates talc litigation setbacks and expands into neuropsychiatry with the Intra-Cellular Therapies acquisition. A look at valuation and investor outlook.

Read more →
Johnson & Johnson (JNJ) Stock Analysis: Innovation, Oncology Pipeline, and Financial Outlook. Latest stock price, dividend yield, and investment strategies.
Mar 27, 2025

Johnson & Johnson (JNJ): Innovation, Market Impact, and Future Outlook

Johnson & Johnson (JNJ) is navigating a dynamic market. Breakthroughs in oncology and neurology, plus U.S. investments, position JNJ for growth.

Read more →
Johnson & Johnson investment, Tremfya approval, and dividend analysis for investors. JNJ stock insights.
Mar 24, 2025

Johnson & Johnson: $55B Investment, Tremfya Approval, and Dividend King Status

Analysis of Johnson & Johnson's $55B U.S. investment, Tremfya's FDA approval for Crohn's, and its Dividend King status. Growth strategy & market impact insights.

Read more →
Johnson & Johnson strategic investments and FDA approvals driving growth; Tremfya Crohn's disease approval and $55B U.S. investment lead the way. JNJ stock analysis.
Mar 21, 2025

Johnson & Johnson (JNJ): FDA Approval, US Investment & Market Impact

JNJ is making headlines with Tremfya's FDA approval for Crohn's, a $55B U.S. investment, and oncology advancements. A dividend aristocrat offering stability.

Read more →
Johnson & Johnson (JNJ) stock performance: balancing innovation, legal challenges, and market dynamics.
Mar 18, 2025

Johnson & Johnson (JNJ): Nipocalimab, Lawsuits, and Dividend Outlook

Johnson & Johnson (JNJ) faces a mix of promising drug developments, legal challenges, and dividend sustainability concerns. Nipocalimab's FDA Fast Track contrasts with Stelara biosimilar risks.

Read more →
Johnson & Johnson stock analysis: Icotrokinra, Kenvue spin-off, ChemImage lawsuit, R&D spending, and defensive stock performance.
Mar 17, 2025

Johnson & Johnson (JNJ): Innovation, Legal Challenges & Market

Comprehensive analysis of Johnson & Johnson (JNJ) examining Icotrokinra's clinical trial results, Kenvue spin-off, ChemImage lawsuit, R&D spending, and defensive stock characteristics.

Read more →
Johnson & Johnson Stock Analysis: JNJ's Pipeline, Dividend Stability, and Low Beta Appeal
Mar 11, 2025

Johnson & Johnson (JNJ) Analysis: Pipeline, Dividends, Volatility

Analysis of Johnson & Johnson's pipeline shifts, Icotrokinra's potential, Aticaprant's setback, and dividend stability amidst market volatility.

Read more →
Johnson & Johnson (JNJ) stock analysis: Icotrokinra potential, Aticaprant setback, and strategic acquisitions. Insights for investors, financial overview, and market outlook.
Mar 10, 2025

Johnson & Johnson (JNJ): Icotrokinra's Promise, Setbacks, and Resilience

JNJ navigates a dynamic healthcare landscape with Icotrokinra's promise, Aticaprant's setback, and strategic acquisitions, influencing market resilience.

Read more →
Johnson & Johnson (JNJ) 2025: Analysis of challenges, MedTech opportunities, and dividend stability for investors. Stay informed on JNJ's performance.
Mar 7, 2025

Johnson & Johnson (JNJ): MedTech Expansion Offsets R&D Setbacks in 2025

Johnson & Johnson faces mixed outlook in 2025. R&D setbacks offset by MedTech growth. Dividend Aristocrat status provides stability amid market volatility.

Read more →
Johnson & Johnson (JNJ) financial analysis: leadership changes, dividend yield, and innovative pharmaceutical product developments driving long-term value.
Mar 5, 2025

Johnson & Johnson (JNJ): Strategic Shifts, Dividends, and Market Outlook

An intraday snapshot on March 5, 2025 detailing JNJ’s leadership transitions, dividend strategy, and innovative product launches.

Read more →
Johnson & Johnson: Biosimilars, Acquisitions, and Market Analysis - Insights for investors on JNJ's challenges and opportunities in the evolving healthcare landscape.
Feb 27, 2025

Johnson & Johnson (JNJ): Navigating Market Trends

Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and market trends, impacting investors. Stay informed with our in-depth analysis.

Read more →
Johnson & Johnson (JNJ) stock analysis: Exploring biosimilar competition, new therapies (TREMFYA), and the Intra-Cellular Therapies acquisition.
Feb 26, 2025

Johnson & Johnson (JNJ): Navigating Biosimilars, Acquisitions, and Market Trends

Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and legal challenges in a dynamic healthcare market. Analysis and key insights provided.

Read more →
Analysis of Johnson & Johnson's challenges, including biosimilar competition and legal battles, and their strategic response.
Feb 25, 2025

Johnson & Johnson (JNJ): Navigating Biosimilars, Legal Battles, and Innovation

Johnson & Johnson navigates biosimilar competition, legal battles, and pharmaceutical innovations, impacting its market position and financial health.

Read more →
Johnson & Johnson: Analysis of Market Trends, Stock Performance, and Strategic Developments in Healthcare - February 2025
Feb 24, 2025

Johnson & Johnson: Developments, Market Impact, and Industry Trends

Analysis of Johnson & Johnson's developments, market impact, and industry trends. Explore the baby powder settlement, biosimilar competition, and TREMFYA's potential.

Read more →
Johnson & Johnson faces biosimilar competition, advances TREMFYA, and navigates baby powder settlement proposal: A strategic analysis.
Feb 21, 2025

J&J Under Pressure: Stelara Biosimilar Arrives as TREMFYA Shows Promise

Johnson & Johnson navigates biosimilar competition, promising TREMFYA data, and legal challenges amid a dynamic healthcare landscape.

Read more →
Johnson & Johnson (JNJ) stock analysis: Litigation impacts, innovation pipeline, and 2025 market outlook.
Feb 21, 2025

Johnson & Johnson: Key Developments, Market Impact, and Industry Trends

Johnson & Johnson navigates legal battles, innovation, and market shifts. Key developments include baby powder litigation and Varipulse rollout. Stay informed.

Read more →
Stock graph trending upwards against a city skyline.
Feb 18, 2025

Johnson & Johnson: Baby Powder Settlement, Pipeline Updates, and Market Impact

A detailed update on JNJ’s legal battles, pipeline shifts, and market performance as the company navigates key challenges.

Read more →
Johnson & Johnson logo on a soft blue gradient background.
Feb 18, 2025

Johnson & Johnson’s $10 Billion Baby Powder Battle: Will It Endure?

An in‐depth update on [JNJ](/dashboard/companies/JNJ)’s legal challenges, pipeline developments and strategic initiatives, with actionable insights for investors.

Read more →